APLS Stock Analysis: Buy, Sell, or Hold?
APLS - Apellis Pharmaceuticals, Inc. Common Stock
$41.03
-0.03 (-0.07%)
▼
5d:
-0.22%
30d:
+0.44%
90d:
+83.91%
BUY
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.5/10
Get Alerted When APLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: APLS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: APLS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: APLS is currently trading at $41.03, which is considered fair based on recent price action. From a valuation perspective, the stock is trading at a discount (Forward PE: -187.9) compared to its historical average (480.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, APLS is in a strong uptrend. The price is currently testing key support at $40.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, APLS is in a strong uptrend. The price is currently testing key support at $40.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
59/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($40.93)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Support & Resistance Levels
Support Level
$40.93
Resistance Level
$41.14
Current Trend
Strong Uptrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-187.95
Wall Street Target
$40.93
(-0.2%)
Revenue Growth (YoY)
60.9%
Profit Margin
12.1%
PE vs Historical
-188.0 vs 480.9
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 8:43 AM ET
Data refreshes hourly during market hours. Next update: 9:43 AM
Data refreshes hourly during market hours. Next update: 9:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Jeffrey Delong
SELL
368 shares
2026-02-11
Caroline Baumal
SELL
2797 shares
2026-01-22
Timothy Eugene Sullivan
SELL
10287 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 64 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 65 BUY |
